Connect with us
Vytrus Biotech's first-quarter 2024 sales surged by 32% compared to 2023, driven by skin and hair care products. The US and European markets led the growth,...
Vertex announced plans to acquire Alpine Immune Sciences for $4.9 billion, primarily for its experimental drug povetacicept to treat IgA nephropathy. Vertex will pay $65 per...
Reig Jofre invests €5.8 million in Leanbio for vertical integration in biotechnology. They increase their stake to 24%, committing to expanding further. The collaboration aims to...
Johnson & Johnson announces the acquisition of Shockwave Medical for $13.1 billion, expanding its presence in cardiovascular intervention. Subject to shareholder and regulatory approval, the deal...
Grifols leads the IBEX 35's mid-morning gains, rising 3.42% to 9.02 euros, marking its fourth consecutive positive day. Despite falling over 40% for the year, the...
ACS Biotech has developed a unique gel in the world capable of repairing cartilage damage occurring following traumatic shock or a degenerative disease such as osteoarthritis....
Rovi has gained FDA approval for its drug Risvan to treat schizophrenia in adults. The approval led to a nearly 3% surge in Rovi's stock. Risvan,...
The Spanish pharma sector faced a downturn in the stock market in Q1 of 2024, with a collective market capitalization drop of 15.8% for six listed...
The European Medicines Agency (EMA) is close to authorizing UCB's new treatment, Bimzelx, for hidradenitis suppurativa. The positive assessment from the Chmp suggests it could be...
PharmaMar started February with falls of almost 3% at the opening of the market. The reason was that Sylentis had failed in its primary objective of...
 |
|
 |  |
 |
|